Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review

Filipe Araujo, Ines Cordeiro, Sofia Ramiro, Louise Falzon, Jaime C Branco, Rachelle Buchbinder

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.OBJECTIVE: The aim of this study was to systematically review outcome domains and measurement tools used in gout trials and their accordance with the preliminary OMERACT gout recommendations published in 2005.METHODS: Randomized controlled trials (RCTs) and quasi-RCTs investigating any intervention for gout published up to February 2013 were included. Recruitment start dates and all measured outcomes were extracted. Risk of bias (RoB) was assessed with the Cochrane Collaboration tool. Numbers of OMERACT domains were compared for trials at low vs unclear/high RoB and for recruitment start date before 2005 or 2005 and later.RESULTS: Of 9784 articles screened, 38 acute and 30 chronic gout trials were included. Mean (s.d.) number of OMERACT outcomes was 2.9 (1.1) (out of 5) and 2.5 (1.2) (out of 9) for acute and chronic gout trials, respectively. Health-related quality of life, participation and joint damage imaging were not assessed in any trial. Tools used to measure individual domains varied widely. There were no differences in the number of OMERACT outcomes reported in acute or chronic gout trials recruiting before 2005 vs 2005 or later [mean (s.d.): 3.0 (1.1) vs 3.5 (1.3), P = 0.859 and 2.7 (1.1) vs 2.8 (1.4), P = 0.960, respectively]. While both acute and chronic trials at low RoB reported more OMERACT domains than trials at unclear/high RoB, these differences were not significant. Industry-funded trials and trials performed by OMERACT investigators reported more OMERACT outcome domains.CONCLUSION: We found no appreciable impact of the OMERACT recommendations for gout trials to date.
Original languageEnglish
Article numberkeu424
Pages (from-to)981-993
Number of pages13
JournalRheumatology
Volume54
Issue number6
DOIs
Publication statusPublished - 1 Jun 2015

Keywords

  • gout
  • outcomes research
  • patient perspective

Cite this

Araujo, Filipe ; Cordeiro, Ines ; Ramiro, Sofia ; Falzon, Louise ; Branco, Jaime C ; Buchbinder, Rachelle. / Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. In: Rheumatology. 2015 ; Vol. 54, No. 6. pp. 981-993.
@article{fc367561d7d54095838b78526611bb8e,
title = "Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review",
abstract = "{\circledC} The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.OBJECTIVE: The aim of this study was to systematically review outcome domains and measurement tools used in gout trials and their accordance with the preliminary OMERACT gout recommendations published in 2005.METHODS: Randomized controlled trials (RCTs) and quasi-RCTs investigating any intervention for gout published up to February 2013 were included. Recruitment start dates and all measured outcomes were extracted. Risk of bias (RoB) was assessed with the Cochrane Collaboration tool. Numbers of OMERACT domains were compared for trials at low vs unclear/high RoB and for recruitment start date before 2005 or 2005 and later.RESULTS: Of 9784 articles screened, 38 acute and 30 chronic gout trials were included. Mean (s.d.) number of OMERACT outcomes was 2.9 (1.1) (out of 5) and 2.5 (1.2) (out of 9) for acute and chronic gout trials, respectively. Health-related quality of life, participation and joint damage imaging were not assessed in any trial. Tools used to measure individual domains varied widely. There were no differences in the number of OMERACT outcomes reported in acute or chronic gout trials recruiting before 2005 vs 2005 or later [mean (s.d.): 3.0 (1.1) vs 3.5 (1.3), P = 0.859 and 2.7 (1.1) vs 2.8 (1.4), P = 0.960, respectively]. While both acute and chronic trials at low RoB reported more OMERACT domains than trials at unclear/high RoB, these differences were not significant. Industry-funded trials and trials performed by OMERACT investigators reported more OMERACT outcome domains.CONCLUSION: We found no appreciable impact of the OMERACT recommendations for gout trials to date.",
keywords = "gout, outcomes research, patient perspective",
author = "Filipe Araujo and Ines Cordeiro and Sofia Ramiro and Louise Falzon and Branco, {Jaime C} and Rachelle Buchbinder",
year = "2015",
month = "6",
day = "1",
doi = "10.1093/rheumatology/keu424",
language = "English",
volume = "54",
pages = "981--993",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. / Araujo, Filipe; Cordeiro, Ines; Ramiro, Sofia; Falzon, Louise; Branco, Jaime C; Buchbinder, Rachelle.

In: Rheumatology, Vol. 54, No. 6, keu424, 01.06.2015, p. 981-993.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review

AU - Araujo, Filipe

AU - Cordeiro, Ines

AU - Ramiro, Sofia

AU - Falzon, Louise

AU - Branco, Jaime C

AU - Buchbinder, Rachelle

PY - 2015/6/1

Y1 - 2015/6/1

N2 - © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.OBJECTIVE: The aim of this study was to systematically review outcome domains and measurement tools used in gout trials and their accordance with the preliminary OMERACT gout recommendations published in 2005.METHODS: Randomized controlled trials (RCTs) and quasi-RCTs investigating any intervention for gout published up to February 2013 were included. Recruitment start dates and all measured outcomes were extracted. Risk of bias (RoB) was assessed with the Cochrane Collaboration tool. Numbers of OMERACT domains were compared for trials at low vs unclear/high RoB and for recruitment start date before 2005 or 2005 and later.RESULTS: Of 9784 articles screened, 38 acute and 30 chronic gout trials were included. Mean (s.d.) number of OMERACT outcomes was 2.9 (1.1) (out of 5) and 2.5 (1.2) (out of 9) for acute and chronic gout trials, respectively. Health-related quality of life, participation and joint damage imaging were not assessed in any trial. Tools used to measure individual domains varied widely. There were no differences in the number of OMERACT outcomes reported in acute or chronic gout trials recruiting before 2005 vs 2005 or later [mean (s.d.): 3.0 (1.1) vs 3.5 (1.3), P = 0.859 and 2.7 (1.1) vs 2.8 (1.4), P = 0.960, respectively]. While both acute and chronic trials at low RoB reported more OMERACT domains than trials at unclear/high RoB, these differences were not significant. Industry-funded trials and trials performed by OMERACT investigators reported more OMERACT outcome domains.CONCLUSION: We found no appreciable impact of the OMERACT recommendations for gout trials to date.

AB - © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.OBJECTIVE: The aim of this study was to systematically review outcome domains and measurement tools used in gout trials and their accordance with the preliminary OMERACT gout recommendations published in 2005.METHODS: Randomized controlled trials (RCTs) and quasi-RCTs investigating any intervention for gout published up to February 2013 were included. Recruitment start dates and all measured outcomes were extracted. Risk of bias (RoB) was assessed with the Cochrane Collaboration tool. Numbers of OMERACT domains were compared for trials at low vs unclear/high RoB and for recruitment start date before 2005 or 2005 and later.RESULTS: Of 9784 articles screened, 38 acute and 30 chronic gout trials were included. Mean (s.d.) number of OMERACT outcomes was 2.9 (1.1) (out of 5) and 2.5 (1.2) (out of 9) for acute and chronic gout trials, respectively. Health-related quality of life, participation and joint damage imaging were not assessed in any trial. Tools used to measure individual domains varied widely. There were no differences in the number of OMERACT outcomes reported in acute or chronic gout trials recruiting before 2005 vs 2005 or later [mean (s.d.): 3.0 (1.1) vs 3.5 (1.3), P = 0.859 and 2.7 (1.1) vs 2.8 (1.4), P = 0.960, respectively]. While both acute and chronic trials at low RoB reported more OMERACT domains than trials at unclear/high RoB, these differences were not significant. Industry-funded trials and trials performed by OMERACT investigators reported more OMERACT outcome domains.CONCLUSION: We found no appreciable impact of the OMERACT recommendations for gout trials to date.

KW - gout

KW - outcomes research

KW - patient perspective

UR - http://www.scopus.com/inward/record.url?scp=84964697343&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keu424

DO - 10.1093/rheumatology/keu424

M3 - Review Article

VL - 54

SP - 981

EP - 993

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 6

M1 - keu424

ER -